November 26, 2014 /3BL Media/- More than half of the 7.2 million people living with diabetes in Turkey have a complication[1] that worsens health and are costly to treat. In 2012, treating complications accounted for 74% of total diabetes expenditures. According to the latest estimates from the International Diabetes Federation, by 2035 Turkey will have the highest absolute number of people with diabetes in Europe.
Novo Nordisk’s newly published Blueprint for Change case study ‘Innovating Diabetes care in Turkey’ shows how investing in local research and development, training of healthcare professionals and strengthening patient self-management programmes can lower costs and improve quality of life.
Read More: http://3blmedia.com/News/Novo-Nordisk-Case-Study-Shows-Path-Lowering-Costs-and-Improving-Diabetes-Care-Turkey
© 2014 | 3BL Media/Novo Nordisk | All Rights Reserved
